| |
|
|
|
Akari Therapeutics  
|
|
1.895 -0.035 (-0.02%) |
08-05 12:37 |
|
Open: |
1.93 |
Pre close: |
1.93 |
Target:
|
2.76 
|
|
High: |
1.95 |
Low: |
1.88 |
Resistance:
|
2.36
2.66
|
|
Volume: |
182,264 |
Market Cap: |
63M |
Support:
|
1.88
1.56
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.97
|
MACD |
MACD(12,26):
|
-0.04 |
|
MA(20): |
2.00 |
Signal(12,26,9): |
-0.03 |
|
MA(100): |
1.87  |
Stochastic Oscillator |
%K(14,3):
|
7.26 |
|
MA(250): |
1.86 |
%D(3): |
18.63 |
|
Average Volume(K) |
3-Month: |
41642
|
52-Week |
High:
|
3.35 |
|
10-Days: |
28565 |
Low: |
0.87 |
|
RSI |
RSI(14):
|
41.15 |
Change(%): |
2.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.927 |
Return on Equity (ttm) |
-1182.3 |
Shares Out. (M) |
33.46 |
|
EPS Est. Current Year |
-2.360 |
Return on Assets (ttm) |
-145.8 |
Shares Float (M) |
13.75 |
|
EPS Est. Next Year |
-3.110 |
PEG Ratio |
0.00 |
% Held by Insiders |
41.85 |
|
EPS Est. Next Quarter |
-0.660 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
3.23 |
|
Forward EPS |
-0.100 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
191 |
|
Book Value (p.s.) |
0.060 |
EBITDA (p.s.) |
-0.654 |
P/E |
-2.05 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
31.67 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-20.89 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-12.00 |
P/CF |
-3.04 |
|
|
|
|
|
|
